• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Syapse Appoints David Pomerantz as Chief Commercial Officer

by Jasmine Pennic 09/03/2020 Leave a Comment

Syapse Appoints David Pomerantz as Chief Commercial Officer
David Pomerantz, Chief Commercial Officer at Syapse

Syapse, a real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health Network™, today announced the appointment of David Pomerantz as Chief Commercial Officer. In his new role as Chief Commercial Officer, Pomerantz will lead the future direction of Syapse’s commercial endeavors and expand its life sciences partnerships across the Syapse Learning Network.

Pomerantz Bio/Background

Mr. Pomerantz brings more than 25 years of account management, commercial and operational experience in the area of real-world evidence for life sciences having most recently come from Kantar Health, a leader in providing data, analytics and research to the life sciences industry. While at Kantar Health for more than a decade, Mr. Pomerantz held increasingly responsible commercial operations positions including leadership of the RWE Client Partner sales team for the Americas and Europe. Most notably, he was responsible for the identification, acquisition and integration of the healthcare consulting firm, Evidencias, now a Kantar Health company, a leader in evidence-based health management services in Brazil focused on oncology and real-world evidence. Under his leadership, Kantar Health successfully entered into an emerging market and bridged the gap between life sciences, payers, providers and regulators.

“Syapse’s mission of using real-world evidence to improve outcomes for patients with cancer is aligned with my passion to innovate patient care by partnering with life sciences companies, health systems and regulators to take action on real-world data insights,” said David Pomerantz, Chief Commercial Officer. “I’m excited to join Syapse in their mission to empower life sciences and health systems to bring the power of precision medicine to patients who need it.”

Tagged With: cancer, Digital Health Hires, Health Systems, Kantar Health, Life Sciences, Oncology, Patient Care, Payers, Precision Medicine, Syapse

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |